ChrisHTakimotoMD

Physician

Dr. Takimoto is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

UniforMed Services University of the Health Sciences F. Edward Hebert School of MedicineFellowship, Clincal Pharmacology and Therapeutics, 1994 - 1996
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1990 - 1993
University of California (San Francisco)Residency, Internal Medicine, 1986 - 1989
Yale School of MedicineClass of 1986

PubMed

179 citations
Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies.
Mark P. Chao, Chris H. Takimoto, Dong Dong Feng, Mckenna Kelly Marie, Phung Gip
Frontiers in Oncology. 2020-01-22
18 citations
Improving attribution of adverse events in oncology clinical trials.
Goldy C. George, Pedro C. Barata, Alicyn Campbell, Alice P. Chen, Jorge E. Cortes
Cancer Treatment Reviews. 2019-06-01
70 citations
The Macrophage 'Do not eat me' signal, CD47, is a clinically validated cancer immunotherapy target.
Chris H. Takimoto, M.P. Chao, C. Gibbs, M.A. McCamish, J. Liu
Annals of Oncology. 2019-03-01

Abstracts/Posters

The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results
Chris H Takimoto, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
An All Antibody Approach for Conditioning Bone Marrow for Hematopoietic Stem Cell Transplantation with Anti-cKIT and Anti-CD47 in Non-Human Primates
Chris H Takimoto, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

IGM Biosciences, Inc. (NASDAQ:IGMS) Q4 2022 Earnings Call TranscriptApril 6th, 2023
Chutes & Ladders—Scholar Rock Founding CEO Returns to Top Spot as Kingsley Swiftly ExitsAugust 6th, 2021
$Forty Seven, Inc. Announces Updated Data from Phase 1b/2 Clinical Trial of 5F9 in Combination with Rituximab in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma$
Forty Seven, Inc. Announces Updated Data from Phase 1b/2 Clinical Trial of 5F9 in Combination with Rituximab in Patients with Relapsed/Refractory Non-Hodgkin’s LymphomaJune 15th, 2019
Join now to see all